Caires Marcella Cabral, Kasuku Keren Mbondo, Mengesha Bethlehem, Garuba Habibat, Law Angeline, Johnson Christopher, Paterson David Ian, Dennie Carole, Pena Elena, Chen Li, Chow Benjamin J W, Small Gary R
Medicine Division of Cardiology, (Cabral Caires, Mbondo Kasuku, Mengesha, Paterson, Chen, Chow, Small), University of Ottawa Heart Institute; Department of Cardiology (Garuba, Law, Johnson), The Ottawa Hospital; Department of Radiology (Dennie, Pena), University of Ottawa, Ottawa, Ont.
CMAJ. 2024 Dec 1;196(41):E1362-E1369. doi: 10.1503/cmaj.231602.
Low-dose chest computed tomography (CT) is used for lung cancer screening, but can also detect coronary artery disease as coronary artery calcium. We sought to determine the prevalence and prognostic utility of coronary artery calcium in a population at high risk of cancer.
We reviewed CT scans from consecutive participants screened for lung cancer between March 2017 and November 2018 as part of the Ontario Health Lung Cancer Screening Pilot for People at High Risk. We quantified coronary artery calcium using an estimated Agatston score. We identified the composite primary outcome of all-cause death and cardiovascular events using linked electronic medical record data from The Ottawa Hospital to December 2023.
Among 1486 people who underwent screening CT, coronary artery calcium was detected in 1232 (82.9%) and was extensive in 439 (29.5%). On multivariable analysis, extensive coronary artery calcium was associated with the composite primary outcome (hazard ratio [HR] 2.13, 95% confidence interval [CI] 1.35-3.38), all-cause death (HR 2.39, 95% CI 1.34-4.27), and cardiovascular events (HR 2.06, 95% CI 1.13-3.77). Extensive coronary artery calcium remained predictive of cardiovascular events after we adjusted for noncardiovascular death as a competing risk (HR 2.05, 95% CI 1.09-3.85).
Among people undergoing low-dose chest CT for lung cancer screening, extensive coronary artery calcium was an independent predictor of all-cause death and cardiovascular events, even after adjustment for noncardiovascular death. The opportunity to identify and reduce risks from coronary artery disease may represent an additional benefit of lung cancer screening.
低剂量胸部计算机断层扫描(CT)用于肺癌筛查,但也能检测出冠状动脉疾病,表现为冠状动脉钙化。我们试图确定癌症高危人群中冠状动脉钙化的患病率及其预后价值。
我们回顾了2017年3月至2018年11月期间连续参与肺癌筛查的参与者的CT扫描结果,这些筛查是安大略省高危人群肺癌筛查试点项目的一部分。我们使用估计的阿加斯顿评分对冠状动脉钙化进行量化。我们利用渥太华医院的电子病历关联数据,确定截至2023年12月的全因死亡和心血管事件这一复合主要结局。
在1486名接受筛查CT的人群中,1232人(82.9%)检测出冠状动脉钙化,其中439人(29.5%)为重度钙化。多变量分析显示,重度冠状动脉钙化与复合主要结局(风险比[HR]2.13,95%置信区间[CI]1.35 - 3.38)、全因死亡(HR 2.39,95% CI 1.34 - 4.27)和心血管事件(HR 2.06,95% CI 1.13 - 3.77)相关。在将非心血管死亡作为竞争风险进行校正后,重度冠状动脉钙化仍可预测心血管事件(HR 2.05,95% CI 1.09 - 3.85)。
在接受低剂量胸部CT进行肺癌筛查的人群中,即使校正了非心血管死亡因素,重度冠状动脉钙化仍是全因死亡和心血管事件的独立预测因素。识别并降低冠状动脉疾病风险的机会可能是肺癌筛查的一项额外益处。